SPP1 and pancreatic adenocarcinoma: For SPP1, patients in the high expression subgroup had significantly unfavorable survival in CESC, COAD, GBM, HNSC, LIHC, LUAD, and had marginally significantly unfavorable survival in LUSC and PAAD.